

# Global Chronic Granulomatous Disease (CGD) Treatment Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GDE71A6AFF07EN.html>

Date: February 2023

Pages: 106

Price: US\$ 4,480.00 (Single User License)

ID: GDE71A6AFF07EN

## Abstracts

The global Chronic Granulomatous Disease (CGD) Treatment market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Chronic Granulomatous Disease (CGD) Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Chronic Granulomatous Disease (CGD) Treatment, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chronic Granulomatous Disease (CGD) Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Chronic Granulomatous Disease (CGD) Treatment total market, 2018-2029, (USD Million)

Global Chronic Granulomatous Disease (CGD) Treatment total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Chronic Granulomatous Disease (CGD) Treatment total market, key domestic companies and share, (USD Million)

Global Chronic Granulomatous Disease (CGD) Treatment revenue by player and market share 2018-2023, (USD Million)

Global Chronic Granulomatous Disease (CGD) Treatment total market by Type, CAGR, 2018-2029, (USD Million)

Global Chronic Granulomatous Disease (CGD) Treatment total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Chronic Granulomatous Disease (CGD) Treatment market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Clinigen Group plc, Orchard Therapeutics plc<sup>2032</sup>, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG and Lonza, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chronic Granulomatous Disease (CGD) Treatment market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Chronic Granulomatous Disease (CGD) Treatment Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

## Global Chronic Granulomatous Disease (CGD) Treatment Market, Segmentation by Type

X-Linked Chronic Granulomatous Disease

Autosomal Recessive Chronic Granulomatous Disease

## Global Chronic Granulomatous Disease (CGD) Treatment Market, Segmentation by Application

Neutrophil Function Tests

Genetic Testing

Prenatal Testing

## Companies Profiled:

Clinigen Group plc

Orchard Therapeutics plc2032

Horizon Therapeutics plc

ViroMed. Co. Ltd

Bellicum Pharmaceuticals, Inc

Pfizer Inc

Hoffmann-La Roche Ltd

Novartis AG

Lonza

GlaxoSmithKline plc

Eli Lilly and Company

Johnson & Johnson Services, Inc

Merck KGaA

#### Key Questions Answered

1. How big is the global Chronic Granulomatous Disease (CGD) Treatment market?
2. What is the demand of the global Chronic Granulomatous Disease (CGD) Treatment market?
3. What is the year over year growth of the global Chronic Granulomatous Disease (CGD) Treatment market?
4. What is the total value of the global Chronic Granulomatous Disease (CGD) Treatment market?
5. Who are the major players in the global Chronic Granulomatous Disease (CGD) Treatment market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Chronic Granulomatous Disease (CGD) Treatment Introduction
- 1.2 World Chronic Granulomatous Disease (CGD) Treatment Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Chronic Granulomatous Disease (CGD) Treatment Total Market by Region (by Headquarter Location)
  - 1.3.1 World Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
  - 1.3.3 China Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
  - 1.3.4 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
  - 1.3.5 Japan Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
  - 1.3.6 South Korea Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
  - 1.3.7 ASEAN Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
  - 1.3.8 India Chronic Granulomatous Disease (CGD) Treatment Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Chronic Granulomatous Disease (CGD) Treatment Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Chronic Granulomatous Disease (CGD) Treatment Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
  - 1.5.1 Influence of COVID-19
  - 1.5.2 Influence of Russia-Ukraine War

### 2 DEMAND SUMMARY

- 2.1 World Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)
- 2.2 World Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Region

2.2.1 World Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Region (2018-2023)

2.2.2 World Chronic Granulomatous Disease (CGD) Treatment Consumption Value Forecast by Region (2024-2029)

2.3 United States Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

2.4 China Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

2.5 Europe Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

2.6 Japan Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

2.7 South Korea Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

2.8 ASEAN Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

2.9 India Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029)

### **3 WORLD CHRONIC GRANULOMATOUS DISEASE (CGD) TREATMENT COMPANIES COMPETITIVE ANALYSIS**

3.1 World Chronic Granulomatous Disease (CGD) Treatment Revenue by Player (2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Chronic Granulomatous Disease (CGD) Treatment in 2022

3.2.3 Global Concentration Ratios (CR8) for Chronic Granulomatous Disease (CGD) Treatment in 2022

3.3 Chronic Granulomatous Disease (CGD) Treatment Company Evaluation Quadrant

3.4 Chronic Granulomatous Disease (CGD) Treatment Market: Overall Company Footprint Analysis

3.4.1 Chronic Granulomatous Disease (CGD) Treatment Market: Region Footprint

3.4.2 Chronic Granulomatous Disease (CGD) Treatment Market: Company Product Type Footprint

3.4.3 Chronic Granulomatous Disease (CGD) Treatment Market: Company Product Application Footprint

- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

## **4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)**

- 4.1 United States VS China: Chronic Granulomatous Disease (CGD) Treatment Revenue Comparison (by Headquarter Location)
  - 4.1.1 United States VS China: Chronic Granulomatous Disease (CGD) Treatment Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  - 4.1.2 United States VS China: Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Chronic Granulomatous Disease (CGD) Treatment Consumption Value Comparison
  - 4.2.1 United States VS China: Chronic Granulomatous Disease (CGD) Treatment Consumption Value Comparison (2018 & 2022 & 2029)
  - 4.2.2 United States VS China: Chronic Granulomatous Disease (CGD) Treatment Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Chronic Granulomatous Disease (CGD) Treatment Companies and Market Share, 2018-2023
  - 4.3.1 United States Based Chronic Granulomatous Disease (CGD) Treatment Companies, Headquarters (States, Country)
  - 4.3.2 United States Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue, (2018-2023)
- 4.4 China Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue and Market Share, 2018-2023
  - 4.4.1 China Based Chronic Granulomatous Disease (CGD) Treatment Companies, Company Headquarters (Province, Country)
  - 4.4.2 China Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue, (2018-2023)
- 4.5 Rest of World Based Chronic Granulomatous Disease (CGD) Treatment Companies and Market Share, 2018-2023
  - 4.5.1 Rest of World Based Chronic Granulomatous Disease (CGD) Treatment Companies, Headquarters (States, Country)
  - 4.5.2 Rest of World Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue, (2018-2023)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Chronic Granulomatous Disease (CGD) Treatment Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 X-Linked Chronic Granulomatous Disease

5.2.2 Autosomal Recessive Chronic Granulomatous Disease

5.3 Market Segment by Type

5.3.1 World Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023)

5.3.2 World Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2024-2029)

5.3.3 World Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2029)

## **6 MARKET ANALYSIS BY APPLICATION**

6.1 World Chronic Granulomatous Disease (CGD) Treatment Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Neutrophil Function Tests

6.2.2 Genetic Testing

6.2.3 Prenatal Testing

6.3 Market Segment by Application

6.3.1 World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023)

6.3.2 World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2024-2029)

6.3.3 World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2029)

## **7 COMPANY PROFILES**

7.1 Clinigen Group plc

7.1.1 Clinigen Group plc Details

7.1.2 Clinigen Group plc Major Business

7.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product and Services



- 7.1.4 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
- 7.1.5 Clinigen Group plc Recent Developments/Updates
- 7.1.6 Clinigen Group plc Competitive Strengths & Weaknesses
- 7.2 Orchard Therapeutics plc2032
  - 7.2.1 Orchard Therapeutics plc2032 Details
  - 7.2.2 Orchard Therapeutics plc2032 Major Business
  - 7.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.2.4 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.2.5 Orchard Therapeutics plc2032 Recent Developments/Updates
  - 7.2.6 Orchard Therapeutics plc2032 Competitive Strengths & Weaknesses
- 7.3 Horizon Therapeutics plc
  - 7.3.1 Horizon Therapeutics plc Details
  - 7.3.2 Horizon Therapeutics plc Major Business
  - 7.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.3.4 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.3.5 Horizon Therapeutics plc Recent Developments/Updates
  - 7.3.6 Horizon Therapeutics plc Competitive Strengths & Weaknesses
- 7.4 ViroMed. Co. Ltd
  - 7.4.1 ViroMed. Co. Ltd Details
  - 7.4.2 ViroMed. Co. Ltd Major Business
  - 7.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.4.4 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.4.5 ViroMed. Co. Ltd Recent Developments/Updates
  - 7.4.6 ViroMed. Co. Ltd Competitive Strengths & Weaknesses
- 7.5 Bellicum Pharmaceuticals, Inc
  - 7.5.1 Bellicum Pharmaceuticals, Inc Details
  - 7.5.2 Bellicum Pharmaceuticals, Inc Major Business
  - 7.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.5.4 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.5.5 Bellicum Pharmaceuticals, Inc Recent Developments/Updates

- 7.5.6 Bellicum Pharmaceuticals, Inc Competitive Strengths & Weaknesses
- 7.6 Pfizer Inc
  - 7.6.1 Pfizer Inc Details
  - 7.6.2 Pfizer Inc Major Business
  - 7.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.6.4 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.6.5 Pfizer Inc Recent Developments/Updates
  - 7.6.6 Pfizer Inc Competitive Strengths & Weaknesses
- 7.7 Hoffmann-La Roche Ltd
  - 7.7.1 Hoffmann-La Roche Ltd Details
  - 7.7.2 Hoffmann-La Roche Ltd Major Business
  - 7.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.7.4 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.7.5 Hoffmann-La Roche Ltd Recent Developments/Updates
  - 7.7.6 Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
- 7.8 Novartis AG
  - 7.8.1 Novartis AG Details
  - 7.8.2 Novartis AG Major Business
  - 7.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.8.4 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.8.5 Novartis AG Recent Developments/Updates
  - 7.8.6 Novartis AG Competitive Strengths & Weaknesses
- 7.9 Lonza
  - 7.9.1 Lonza Details
  - 7.9.2 Lonza Major Business
  - 7.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Product and Services
  - 7.9.4 Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
  - 7.9.5 Lonza Recent Developments/Updates
  - 7.9.6 Lonza Competitive Strengths & Weaknesses
- 7.10 GlaxoSmithKline plc
  - 7.10.1 GlaxoSmithKline plc Details
  - 7.10.2 GlaxoSmithKline plc Major Business

7.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product and Services

7.10.4 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)

7.10.5 GlaxoSmithKline plc Recent Developments/Updates

7.10.6 GlaxoSmithKline plc Competitive Strengths & Weaknesses

7.11 Eli Lilly and Company

7.11.1 Eli Lilly and Company Details

7.11.2 Eli Lilly and Company Major Business

7.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product and Services

7.11.4 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)

7.11.5 Eli Lilly and Company Recent Developments/Updates

7.11.6 Eli Lilly and Company Competitive Strengths & Weaknesses

7.12 Johnson & Johnson Services, Inc

7.12.1 Johnson & Johnson Services, Inc Details

7.12.2 Johnson & Johnson Services, Inc Major Business

7.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product and Services

7.12.4 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)

7.12.5 Johnson & Johnson Services, Inc Recent Developments/Updates

7.12.6 Johnson & Johnson Services, Inc Competitive Strengths & Weaknesses

7.13 Merck KGaA

7.13.1 Merck KGaA Details

7.13.2 Merck KGaA Major Business

7.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product and Services

7.13.4 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)

7.13.5 Merck KGaA Recent Developments/Updates

7.13.6 Merck KGaA Competitive Strengths & Weaknesses

## **8 INDUSTRY CHAIN ANALYSIS**

8.1 Chronic Granulomatous Disease (CGD) Treatment Industry Chain

8.2 Chronic Granulomatous Disease (CGD) Treatment Upstream Analysis

8.3 Chronic Granulomatous Disease (CGD) Treatment Midstream Analysis

## 8.4 Chronic Granulomatous Disease (CGD) Treatment Downstream Analysis

## **9 RESEARCH FINDINGS AND CONCLUSION**

## **10 APPENDIX**

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. World Chronic Granulomatous Disease (CGD) Treatment Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
- Table 2. World Chronic Granulomatous Disease (CGD) Treatment Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
- Table 3. World Chronic Granulomatous Disease (CGD) Treatment Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
- Table 4. World Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Region (2018-2023), (by Headquarter Location)
- Table 5. World Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Region (2024-2029), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Chronic Granulomatous Disease (CGD) Treatment Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
- Table 8. World Chronic Granulomatous Disease (CGD) Treatment Consumption Value by Region (2018-2023) & (USD Million)
- Table 9. World Chronic Granulomatous Disease (CGD) Treatment Consumption Value Forecast by Region (2024-2029) & (USD Million)
- Table 10. World Chronic Granulomatous Disease (CGD) Treatment Revenue by Player (2018-2023) & (USD Million)
- Table 11. Revenue Market Share of Key Chronic Granulomatous Disease (CGD) Treatment Players in 2022
- Table 12. World Chronic Granulomatous Disease (CGD) Treatment Industry Rank of Major Player, Based on Revenue in 2022
- Table 13. Global Chronic Granulomatous Disease (CGD) Treatment Company Evaluation Quadrant
- Table 14. Head Office of Key Chronic Granulomatous Disease (CGD) Treatment Player
- Table 15. Chronic Granulomatous Disease (CGD) Treatment Market: Company Product Type Footprint
- Table 16. Chronic Granulomatous Disease (CGD) Treatment Market: Company Product Application Footprint
- Table 17. Chronic Granulomatous Disease (CGD) Treatment Mergers & Acquisitions Activity
- Table 18. United States VS China Chronic Granulomatous Disease (CGD) Treatment Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 19. United States VS China Chronic Granulomatous Disease (CGD) Treatment

Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Chronic Granulomatous Disease (CGD) Treatment Companies, Headquarters (States, Country)

Table 21. United States Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share (2018-2023)

Table 23. China Based Chronic Granulomatous Disease (CGD) Treatment Companies, Headquarters (Province, Country)

Table 24. China Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share (2018-2023)

Table 26. Rest of World Based Chronic Granulomatous Disease (CGD) Treatment Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share (2018-2023)

Table 29. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023) & (USD Million)

Table 31. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2024-2029) & (USD Million)

Table 32. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023) & (USD Million)

Table 34. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2024-2029) & (USD Million)

Table 35. Clinigen Group plc Basic Information, Area Served and Competitors

Table 36. Clinigen Group plc Major Business

Table 37. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 38. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Clinigen Group plc Recent Developments/Updates

Table 40. Clinigen Group plc Competitive Strengths & Weaknesses

- Table 41. Orchard Therapeutics plc2032 Basic Information, Area Served and Competitors
- Table 42. Orchard Therapeutics plc2032 Major Business
- Table 43. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product and Services
- Table 44. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 45. Orchard Therapeutics plc2032 Recent Developments/Updates
- Table 46. Orchard Therapeutics plc2032 Competitive Strengths & Weaknesses
- Table 47. Horizon Therapeutics plc Basic Information, Area Served and Competitors
- Table 48. Horizon Therapeutics plc Major Business
- Table 49. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product and Services
- Table 50. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 51. Horizon Therapeutics plc Recent Developments/Updates
- Table 52. Horizon Therapeutics plc Competitive Strengths & Weaknesses
- Table 53. ViroMed. Co. Ltd Basic Information, Area Served and Competitors
- Table 54. ViroMed. Co. Ltd Major Business
- Table 55. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product and Services
- Table 56. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 57. ViroMed. Co. Ltd Recent Developments/Updates
- Table 58. ViroMed. Co. Ltd Competitive Strengths & Weaknesses
- Table 59. Bellicum Pharmaceuticals, Inc Basic Information, Area Served and Competitors
- Table 60. Bellicum Pharmaceuticals, Inc Major Business
- Table 61. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product and Services
- Table 62. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 63. Bellicum Pharmaceuticals, Inc Recent Developments/Updates
- Table 64. Bellicum Pharmaceuticals, Inc Competitive Strengths & Weaknesses
- Table 65. Pfizer Inc Basic Information, Area Served and Competitors
- Table 66. Pfizer Inc Major Business
- Table 67. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product and Services
- Table 68. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross

Margin and Market Share (2018-2023) & (USD Million)

Table 69. Pfizer Inc Recent Developments/Updates

Table 70. Pfizer Inc Competitive Strengths & Weaknesses

Table 71. Hoffmann-La Roche Ltd Basic Information, Area Served and Competitors

Table 72. Hoffmann-La Roche Ltd Major Business

Table 73. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 74. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. Hoffmann-La Roche Ltd Recent Developments/Updates

Table 76. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses

Table 77. Novartis AG Basic Information, Area Served and Competitors

Table 78. Novartis AG Major Business

Table 79. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 80. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. Novartis AG Recent Developments/Updates

Table 82. Novartis AG Competitive Strengths & Weaknesses

Table 83. Lonza Basic Information, Area Served and Competitors

Table 84. Lonza Major Business

Table 85. Lonza Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 86. Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. Lonza Recent Developments/Updates

Table 88. Lonza Competitive Strengths & Weaknesses

Table 89. GlaxoSmithKline plc Basic Information, Area Served and Competitors

Table 90. GlaxoSmithKline plc Major Business

Table 91. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 92. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. GlaxoSmithKline plc Recent Developments/Updates

Table 94. GlaxoSmithKline plc Competitive Strengths & Weaknesses

Table 95. Eli Lilly and Company Basic Information, Area Served and Competitors

Table 96. Eli Lilly and Company Major Business

Table 97. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product and Services



Table 98. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 99. Eli Lilly and Company Recent Developments/Updates

Table 100. Eli Lilly and Company Competitive Strengths & Weaknesses

Table 101. Johnson & Johnson Services, Inc Basic Information, Area Served and Competitors

Table 102. Johnson & Johnson Services, Inc Major Business

Table 103. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 104. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 105. Johnson & Johnson Services, Inc Recent Developments/Updates

Table 106. Merck KGaA Basic Information, Area Served and Competitors

Table 107. Merck KGaA Major Business

Table 108. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product and Services

Table 109. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 110. Global Key Players of Chronic Granulomatous Disease (CGD) Treatment Upstream (Raw Materials)

Table 111. Chronic Granulomatous Disease (CGD) Treatment Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Chronic Granulomatous Disease (CGD) Treatment Picture

Figure 2. World Chronic Granulomatous Disease (CGD) Treatment Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Chronic Granulomatous Disease (CGD) Treatment Total Market Size (2018-2029) & (USD Million)

Figure 4. World Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Chronic Granulomatous Disease (CGD) Treatment Revenue (2018-2029) & (USD Million)

Figure 13. Chronic Granulomatous Disease (CGD) Treatment Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 16. World Chronic Granulomatous Disease (CGD) Treatment Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 18. China Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 23. India Chronic Granulomatous Disease (CGD) Treatment Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Chronic Granulomatous Disease (CGD) Treatment by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Chronic Granulomatous Disease (CGD) Treatment Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Chronic Granulomatous Disease (CGD) Treatment Markets in 2022

Figure 27. United States VS China: Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Chronic Granulomatous Disease (CGD) Treatment Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type in 2022

Figure 31. X-Linked Chronic Granulomatous Disease

Figure 32. Autosomal Recessive Chronic Granulomatous Disease

Figure 33. World Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2029)

Figure 34. World Chronic Granulomatous Disease (CGD) Treatment Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application in 2022

Figure 36. Neutrophil Function Tests

Figure 37. Genetic Testing

Figure 38. Prenatal Testing

Figure 39. Chronic Granulomatous Disease (CGD) Treatment Industrial Chain

Figure 40. Methodology

Figure 41. Research Process and Data Source

## I would like to order

Product name: Global Chronic Granulomatous Disease (CGD) Treatment Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GDE71A6AFF07EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDE71A6AFF07EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

